Telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with fluorouracil, leucovorin, and budigalimab in locally advanced/metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (a/m GEA).

Authors: Kohei Shitara, Elena Elimova, Zev A. Wainberg, Dani Ran Castillo, Li-Yuan Bai, Murtaza Bhuriwala, John Stewart Hrom, Chloe Xia, Ibrahim Abdelgawad, Raluca Predoiu, Nandini Rudra-Ganguly, Rachel S. Leibman, Graham Walker, Ming-Huang Chen, Jen-Shi Chen, Xiaotian Zhang, Do-Youn Oh

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps4202

Source: Full article

---

Abstract

TPS4202